So far, neither Kennedy nor Trump has announced a real effort to make a pharma advertising ban a reality. But it’s hard to ...

Latigo Biotherapeutics has tapped into investor interest in pain relief medicines with new, non-opioid mechanisms of action, ...

Taiho is parting with $400 million upfront for Araris, a spin-off from the Paul-Scherrer-Institute in Zurich, Switzerland, ...

As Global SME of Life Science and Pharma at Tive, Alex Guillen leads sales and business development within the company's rapid-growth life sciences division. Previously, Guillen served as a Board ...

The Japanese pharma company – currently in the process of rolling out new amyloid-targeting Alzheimer's therapy Leqembi ...

AbbVie has pointed to a very strong launch trajectory for Elahere, with sales rocketing to $480 million last year, almost ...

Measles cases in the European region doubled to 127,350 in 2024, reaching the highest level in nearly three decades and ...

Today, any pharma marketing strategy has to take into account the perspective of multiple stakeholders, such as doctors, regulators, payers and the patient. Here, we speak with Dr Simone Seiter ...

In this new series, we will be interviewing five oncologists from a range of different demographics to find out how they prefer to engage with pharma and how this could be improved in the future.

These have been dark days for the global economy, and the short-term prospects for the pharmaceutical industry look uncertain. The industry is currently undergoing change and restructuring on an ...

Threshold Pharma is to go ahead with Phase 3 clinical trials of its only drug, TH-302, despite recent Phase 2 trials failing to show statistically significant improvement in overall survival.

Novartis has another phase 3 trial win in its quiver for targeted factor B inhibitor iptacopan, building the case for the drug as a new oral therapy for diseases caused by disorders of the ...